Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

ARISTOTELES · Applying ARtificial Intelligence to Define clinical trajectorieS for personalized predicTiOn and early deTEctiOn of comorbidiTy and muLtimorbidiTy pattErnS

HORIZONStatus: SIGNED1 November 202331 October 2028EU funding €4,093,463Call HORIZON-HLTH-2022-STAYHLTH-01-two-stage

The ARISTOTELES project aims to build a multinational harmonized data platform to develop and implement novel artificial intelligence (AI) approaches for management of complex diseases, where progression and manifestations of comorbidities are via multiple interacting pathways. We aim to apply our novel approach to a population of great need due to atrial fibrillation (AF), but our outputs can be extended to other complex diseases with multimorbidity. By integrating AIs into clinical practice, our platform will form a backbone for acceptable, responsible, and respectful uses of patient/participant data to develop and validate novel trustworthy AI tools for more personalized risk assessment and management. This represents a paradigm shift in AF treatment, moving from a focus on individual risk factors and selected outcomes (eg. stroke) to a holistic approach, underpinning timely diagnostic and therapeutic interventions to reduce disease progression, disability, hospitalizations and mortality, as well as improve patient adherence to lifestyle modifications, medications, and other treatment regimens.ARISTOTELES will be delivered through 8 inter-linking work-packages (WPs): WP1 is study management/coordination. WP2 provides the ethical/legal requirements for the development of a trustworthy AI. WP3 addresses stakeholder understanding of AI, needs assessment, and engagement in all the phases of the AI development. In WP4, granular data on genotype and phenotype characteristics, are harmonized from different datasets into a common platform. In WP5, AI algorithms/tools are developed and connected to an interactive output interface for patients and clinicians. In WP6, we test the AI tool developed in WP5 in a clinical trial simulation (in silico trial). In WP7 a multicenter randomized trial runs across multiple countries including both primary care and secondary care. WP7 and WP8 drive the clinical implementation and dissemination of results.

Consortium · 18 organisations

coordinator

UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA

IT · €970,500

associatedPartner

THE UNIVERSITY OF MANCHESTER

UK

participant

IOTIC SOLUTIONS SL

ES · €353,750

participant

GERS SAS

FR · €225,250

participant

PANEPISTIMIO KRITIS

EL · €249,625

associatedPartner

LIVERPOOL JOHN MOORES UNIVERSITY

UK

participant

MOVERIM SRL

BE · €212,750

participant

UNIVERSIDAD DE MURCIA

ES · €287,500

participant

UNIVERSIDADE DE COIMBRA

PT · €16,094

participant

UNIVERSITETET I OSLO

NO · €218,963

associatedPartner

THE UNIVERSITY OF LIVERPOOL

UK

associatedPartner

IDOVEN 1903 SL

ES

associatedPartner

DATARIVER SRL

IT

associatedPartner

UNIVERSITY COLLEGE LONDON

UK

associatedPartner

AIMES MANAGEMENT SERVICES LIMITED

UK

participant

AALBORG UNIVERSITET

DK · €920,025

participant

UNIVERSITATEA DE MEDICINA SI FARMACIE CAROL DAVILA DIN BUCURESTI

RO · €86,531

participant

FONDAZIONE PER IL TUO CUORE ONLUS

IT · €552,475

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.